Form 4 for DMRA Damora Therapeutics, Inc.
Accepted 2026-02-12 00:00:00 ET · period of report 2026-02-09 · accession 0001193125-26-047537 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-12 | 2026-02-09 | DMRA | Bruno Julianne | Dir | M - OptEx | $0.00 | +129.0K | 137.0K | +1,606% | $0 |
| D | 2026-02-12 | 2026-02-09 | DMRA | Bruno Julianne | Dir | M - OptEx | $0.00 | -129 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-09 | M | A | 129,000 | $0.00 | 137,032 | D | — | — | |
| 2 | Derivative | Series C Preferred Stock | 2026-02-09 | M | D | 129 | $0.00 | 0 | D | — · — to — | 129,000 Common Stock | (F3) Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. |